Page 1

Exhibit 99.1 MARKER Therapeutics Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated in Q1 2022 Company to host year - end conference call and webcast in Q1 2022 Houston , TX ― November 10 , 2021 — Marker Therapeutics , Inc. ( Nasdaq : MRKR ) , a clinical - stage immuno - oncology company specializing in the development of next - generation T cell - based immunotherapies for the treatment of hematological malignancies and solid tumor indications , today provided a corporate update and reported financial results for the third quarter ended September 30 , 2021 . " This quarter , we continued our momentum in advancing Marker's Phase 2 trial of MT - 401 , Marker's lead MultiTAA - specific T cell therapy , for the treatment of post - transplant acute myeloid leukemia , or AML , " said Peter L. Hoang , President & CEO of Marker Therapeutics . " We are pleased to announce that the first patients in Marker's Phase 2 AML trial have been dosed with study drug . Further , we are on track to enroll the first 20 patients of the trial in the fourth quarter , with the first data readout expected in the first quarter of 2022. We look forward to providing year - end updates in a conference call and webcast early next year . " PROGRAM UPDATES The Company continues to enroll patients and activate clinical sites across the U.S. in Marker's Phase 2 trial of MT - 401 , its lead MultiTAA- specific T cell product candidate , for the treatment of post - transplant AML . The trial is expected to enroll approximately 120 patients in the adjuvant setting and 40 patients with active disease at approximately 20 clinical sites . BUSINESS UPDATES The Company's new cGMP manufacturing facility in Houston , Texas is fully operational and is supporting ongoing operations . The facility will also manufacture Marker's MultiTAA - specific T cell products for future hematological and solid tumor trials , in addition to producing the potential commercial supply of any products , if approved . In August , the Company announced that it received notice of a Product Development Research award totaling approximately $ 13.1 million from the Cancer Prevention and Research Institute of Texas ( CPRIT ) to support the Company's Phase 2 AML trial .